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Introduction
Juvenile dermatomyositis (JDM) is an uncommon
vasculitis in childhood. JDM is the most prevalent idio-
pathic inflammatory myopathies of childhood. JDM is
characterized by proximal muscle weakness and typical
skin involvement.
Objectives
To describe demographics, clinical features, laboratory
findings and treatment modalities of patients with juvenile
dermatomyositis (JDM) at a referral pediatric rheumatol-
ogy center in Turkey.
Methods
Retrospective review of forty three patients meeting Bohan
and Peter criteria diagnosed as JDM at the Pediatric
Rheumatology Department of Istanbul University
Cerrahpasa Medical Faculty between the years 2003-2013.
Results
Forty three patients were identified; thirty of them
(69.3%) were female, thirteen of them (%30.2) male.
Mean follow-up period was 48 months (3-168). Mean
age for the beginning of the disease was 6.3+/-4.4, mean
age for the diagnosis was 6.9+/-4.4. Forty two patients
(97.7%) had heliotropic rash and Gottron papules,
39 patients (90.7%) had muscle weakness, 36 patients
(87.3%) had erythroderma and 16 patients (37.2%) had
calcinosis as the most common clinical features of the
disease. Forty one of the patients (95%) had elevated
acute phase responses at presentation. Twenty seven of
the patients (62.8%) had anti-nuclear antibody (ANA)
positivity. Anti-jo 1 and antibodies to extractable nuclear
antigen positivity were not found at all. Mean creatine
kinase levels at presentation were 2245+/-3404 IU/L,
median level was 564 IU/L. Mean time returning to
normal levels was 6.6+/-17.8 months, median time was
3 months. Muscle biopsy was performed on 14 patients
(32.6%) and all of them showed findings of inflammatory
myopathy. Electromyography (EMG) was performed on
25 patients (58.1%) and all of them suggested inflamma-
tory myopathy. All patients had been treated with corti-
costeroids at different dosages. Methotrexate was used in
41 patients (95.3%), at the mean dosage of 14.5+/-7.1
(7.5-40) miligrams per week and for the mean duration
of 45+/-36 months. Cyclosporine was used in 16 patients
(37.2%). In 13 of 16 patients with calcinosis (81.3%),
alendronate was used. Muscle weakness was present in
39 patients (90.7%) in the beginning, mean duration for
the recovery of muscle weakness was 7.9+/-10 months,
median duration was 4 months. Only two patients on
follow-up period could not achieve self-movement
capability. Both were referred to our clinic after a long
duration of the disease and had widespread calcinosis.
There were no significant relationship between mean
duration of the muscle enzymes to return normal values
and mean duration of the disappearance of the muscle
weakness (p=0.7).
Conclusion
Juvenile dermatomyositis is a rare systemic vasculopa-
thy; however, it is an important disease because it may
cause severe muscle weakness and paralysis. JDM should
be keep in mind by its presentation as muscle weakness
and different skin rashes in early childhood. It should be
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Methotrexate and prednisolone should be first choices
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